L-DOPA-13C
CAT:
804-HY-N0304S2-01
Size:
1 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No
L-DOPA-13C
- CAS Number: 586971-29-1
- UNSPSC Description: L-DOPA-13C is the 13C labeled L-DOPA[1]. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[2][3][4].
- Target Antigen: Dopamine Receptor; Endogenous Metabolite
- Type: Isotope-Labeled Compounds
- Related Pathways: GPCR/G Protein;Metabolic Enzyme/Protease;Neuronal Signaling
- Applications: Metabolism-protein/nucleotide metabolism
- Field of Research: Neurological Disease
- Assay Protocol: https://www.medchemexpress.com/l-dopa-13c.html
- Purity: 98.0
- Solubility: 0.1 M HCL : 20 mg/mL (ultrasonic;warming;adjust pH to pH to 2 with HCl)
- Smiles: O[13C]([C@@H](N)CC1=CC(O)=C(C=C1)O)=O
- Molecular Weight: 198.18
- References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]Hyland K, et al. Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology. Clin Chem. 1992 Dec;38(12):2405-10.|[3]Merims D, et al. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease. Parkinsonism Relat Disord. 200814(4):273-80. Epub 2007 Nov 7.|[4]Perez-Pardo P, et al. Additive Effects of Levodopa and a Neurorestorative Diet in a Mouse Model of Parkinson's Disease. Front Aging Neurosci. 2018 Aug 310:237.|[5]Park HJ, et al. Anti-allodynic effects of levodopa in neuropathic rats. Yonsei Med J. 2013 Mar 154(2):330-5.
- Shipping Conditions: Room Temperature
- Storage Conditions: 4°C (Powder, stored under nitrogen)
- Clinical Information: No Development Reported